688314.SH
Kontour (Xi'an) Medical Technology Co., Ltd.
SSE · Healthcare · Medical - Devices · CN
CNY 27.54
+2.57%Oct 28, 2026, 09:15 UTC
Kangtuo Medical reported revenue of RMB 260 million for the first three quarters of 2026, up 3.56% year over year, and net profit attributable to shareholders of RMB 61.3008 million, down 20.09%.
Source:Oct 28, 2026, 09:15 UTC
Kangtuo Medical reported third-quarter 2026 revenue of RMB 89.0588 million, up 10.26% year over year, and net profit attributable to shareholders of RMB 19.9071 million, down 8.33%.
Source:Aug 27, 2026, 10:52 UTC
Kangtuo Medical proposed a cash dividend of 1.5 yuan per 10 shares (tax inclusive), totaling 12.2442 million yuan.
Source:Aug 27, 2026, 10:52 UTC
Kangtuo Medical announced its H1 2026 results: net profit attributable to shareholders was 41.39 million yuan, down 24.74% year-on-year.
Source:Aug 25, 2026, 09:13 UTC
Kangtuo Medical's controlled subsidiary Xi'an Meiyan Tianshi Biotechnology Co., Ltd. obtained a Class III medical device registration certificate from China's National Medical Products Administration for injectable cross-linked sodium hyaluronate gel, used for correcting moderate-to-severe neck wrinkles, valid until August 23, 2031.
Source: